Home > Insider Trading > Filing (0001415889-24-025354)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1736730	Camp4 Therapeutics Corp	CAMP	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1953107	Enavate Sciences Gp, Llc	2882 Sand Hill Road, Suite 100 Menlo Park CA 94025		No	No	No	No
2040426	Everest Aggregator, Lp	106 West 56Th Street, 8Th Floor New York NY 10019		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-10-15	2,422,166	$0.00	2,422,166	No	4	C	Indirect	By Everest Aggregator, LP
Common Stock	Acquisiton	2024-10-15	1,363,636	$11.00	3,785,802	No	4	P	Indirect	By Everest Aggregator, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Everest Aggregator, LP
No	4	P	Indirect	By Everest Aggregator, LP

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2024-10-15	27,166,530	$0.00	2,422,166	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.